Abstract:Abstract Abstract 3969 Objective: Although many strategies have been explored to overcome the multidrug resistance (MDR) in leukemia which has rendered many currently available chemotherapeutic drugs ineffective, the results have been disappointing to the obstacle. The aim of this study was to investigate whether the new strategy of combining drug-loaded nanoparticles (Nps) and ultrasound (US) would show useful effects on the reversal of MDR in human leukemia cell line K562/A02. Methods: In this study, daunorubicin (DNR), a frequently chemotherapeutic agent known to cause DNA damage and induce apoptosis and cell death, was loaded on the TiO2 Nps which is chemically stable, environmental friendly, and shows weak or non cytotoxic to apply as the nano-drug carrier. The MDR leukemia K562/A02 cells were treated with the DNR-loaded TiO2 Nps drug carrier and US exposure. Then, we examined the effectiveness of delivering DNR into the MDR leukemia K562/A02 cells with the electrochemical studies, observed the bio-effects on the cell viability by MTT assays, investigated the induced apoptosis, and assessed the reversal ability and the mechanism of MDR by combining the drug-loaded Nps and US. Results: We observed good biocompatibility of the therapeutic approach. When the K562/A02 cells were incubated with DNR only, the cathodic current decreased by only 10% normalized to the DNR (10 μg/mL) standard, indicating less DNR was absorbed by the MDR cells. The cathodic current decreased by 39% and 63% in the presence of US or DNR-loaded TiO2 Nps, respectively. In comparison, when the cells were treated by the novel strategy of US mediated drug-loaded Nps crossing cell membranes, the cathodic current of DNR in the supernatant decreased greatly by 82% and became the minimal, which suggesting the least amount of DNR remained outside the MDR cells in this case and the largest uptake into the cells by this new strategy. These observations demonstrated that the remarkable synergistic effect of the novel strategy facilitated the accumulation of DNR in the MDR K562/A02 cells. In addition, our MTT assay illustrated comparative sensitization of the MDR K562/A02 cells under the treatment of US or drug-loaded Nps, but especially enhanced effect by combining drug-loaded Nps and US. The resisting fold of the MDR leukemia K562/A02 became obviously lower, decreasing from 58.71 to 16.69. The fresh evidence from caspase-3 immunocytochemistry demonstrated that the strategy could induce the apoptosis in the cells as well. Conclusion: It was therefore concluded that the strategy could have good reversal ability of MDR in tumor. These findings reveal that the reversal of MDR in tumor by US mediated drug-loaded Nps crossing cell membranes could represent promising approach in cancer therapy. Disclosures: No relevant conflicts of interest to declare.

Co-delivery of Doxorubicin and MDR1 shRNA by Mesoporous Silica Nanoparticles to Overcome Drug Resistance in vitro

Regulation of Ca2+ Signaling for Drug-Resistant Breast Cancer Therapy with Mesoporous Silica Nanocapsule Encapsulated Doxorubicin/siRNA Cocktail

Mesoporous Silica Nanoparticles Loading Doxorubicin Reverse Multidrug Resistance: Performance And Mechanism

Codelivery of an Optimal Drug/sirna Combination Using Mesoporous Silica Nanoparticles to Overcome Drug Resistance in Breast Cancer in Vitro and in Vivo.

Reversal of Multidrug Resistance by Magnetic Fe3o4 Nanoparticle Copolymerizating Daunorubicin and Mdr1 Shrna Expression Vector in Leukemia Cells

Ultrasound Mediated Drug-Loaded Nanoparticles Crossing Cell Membranes As A New Strategy To Reverse Multidrug Resistance In Human Leukemia Cell Line K562/A02

Co-delivery of multiple drug resistance inhibitors by polymer/inorganic hybrid nanoparticles to effectively reverse cancer drug resistance

Co-Delivery of Doxorubicin and Survivin Shrna-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.

Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy

Reversing of Multidrug Resistance Breast Cancer by Co-Delivery of P-gp Sirna and Doxorubicin Via Folic Acid-Modified Core-Shell Nanomicelles

Doxorubicin and Sirna Co-Delivery System Based on Carbon Dots Inhibits Chemoresistance of Lung Cancer Through MRP1

Doxorubicin and siRNA Co-Delivery System Based on Carbon Dots Inhibits Metastasis of Lung Cancer by Attenuating Mrp1-Mediated Resistance

Overcoming multidrug resistance by co-delivering of MDR1 targeting siRNA and doxorubicin using EphA10-mediated pH-sensitive lipoplexes：In vitro and in vivo evaluation.

Co-Delivery of Doxorubicin and Sirna with Reduction and Ph Dually Sensitive Nanocarrier for Synergistic Cancer Therapy

Systemic Codelivery of Thymoquinone and Doxorubicin by Targeted Mesoporous Silica Nanoparticle Sensitizes Doxorubicin-Resistant Breast Cancer by Interfering between the MDR1/P-gp and miR 298 Crosstalk

Co-delivery of Doxorubicin and P-gp Sirna into Human Breast Cancer Cells by Functionalized PLGA Nanobubbles and Ultrasound Imaging in Vitro.

Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin nanocarrier

Increasing The Cytotoxicity Of Doxorubicin In Breast Cancer Mcf-7 Cells With Multidrug Resistance Using A Mesoporous Silica Nanoparticle Drug Delivery System

Co-delivery of DOX and PDTC by Ph-Sensitive Nanoparticles to Overcome Multidrug Resistance in Breast Cancer.

A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer

Simultaneous Delivery of Anti-Mir21 with Doxorubicin Prodrug by Mimetic Lipoprotein Nanoparticles for Synergistic Effect Against Drug Resistance in Cancer Cells.